Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOKNYSE:JATTNASDAQ:MTEXNASDAQ:NRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$2.96+0.2%$2.87$1.94▼$12.32$4.41M0.04123,725 shs8,187 shsJATTJATT Acquisition$1.26+9.6%$1.20$7.80▼$12.38$21.74MN/A41,322 shs995,683 shsMTEXMannatech$10.39-2.6%$9.91$6.75▼$16.49$19.76M0.924,496 shs3,552 shsNRSNNeuroSense Therapeutics$1.90+6.1%$1.20$0.51▼$1.90$25.97M1.62257,278 shs275,829 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%-12.10%-6.05%-22.86%-56.10%JATTJATT Acquisition0.00%+24.75%+2.44%0.00%-68.58%MTEXMannatech0.00%+2.34%-8.69%-14.13%+30.25%NRSNNeuroSense Therapeutics0.00%+16.99%+71.49%+65.39%+62.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVOKEvoke Pharma0.0516 of 5 stars0.03.00.00.00.00.00.0JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech0.6961 of 5 stars0.04.00.00.01.81.70.0NRSNNeuroSense Therapeutics1.5594 of 5 stars3.53.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/AMTEXMannatech 0.00N/AN/AN/ANRSNNeuroSense Therapeutics 3.00Buy$14.00636.84% UpsideCurrent Analyst Ratings BreakdownLatest EVOK, JATT, MTEX, and NRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$11.59M0.38N/AN/A($9.26) per share-0.32JATTJATT AcquisitionN/AN/A$0.05 per share27.08($0.53) per shareN/AMTEXMannatech$115.04M0.17N/AN/A$5.64 per share1.84NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.14) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$7.79M-$2.87N/A∞N/A-71.32%-308.49%-53.66%8/11/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AMTEXMannatech-$2.24M-$0.10N/A∞N/A-1.26%-15.62%-3.76%8/11/2025 (Estimated)NRSNNeuroSense Therapeutics-$11.28M-$0.54N/A∞N/AN/AN/A-590.79%6/24/2025 (Estimated)Latest EVOK, JATT, MTEX, and NRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/24/2025Q1 2025NRSNNeuroSense Therapeutics-$0.13N/AN/AN/AN/AN/A5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/A3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 million3/13/2025Q4 2024EVOKEvoke Pharma-$0.25-$0.49-$0.24-$0.49$3.08 million$3.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AMTEXMannatech$0.201.92%N/AN/A N/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.441.39JATTJATT AcquisitionN/A0.150.15MTEXMannatech0.441.250.74NRSNNeuroSense TherapeuticsN/A0.21N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/AJATTJATT Acquisition47.97%MTEXMannatech12.98%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%JATTJATT Acquisition20.00%MTEXMannatech41.50%NRSNNeuroSense Therapeutics27.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableMTEXMannatech2501.90 million1.10 millionNot OptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableEVOK, JATT, MTEX, and NRSN HeadlinesRecent News About These CompaniesTop Nasdaq Companies by Market Cap Ranked by KalkineJune 7 at 9:01 AM | kalkinemedia.comNeurosense, awaiting Canada approval, scales PrimeC productionMay 15, 2025 | alsnewstoday.comD. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy RecommendationMay 14, 2025 | msn.comWhy This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsMay 12, 2025 | benzinga.comNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market LaunchMay 7, 2025 | prnewswire.comNeuroSense Therapeutics Advances ALS Treatment and Strategic PartnershipApril 24, 2025 | tipranks.comNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership UpdateApril 24, 2025 | prnewswire.comNeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN MeetingApril 10, 2025 | sohu.comNeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business UpdatesApril 10, 2025 | sohu.comNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS TreatmentApril 9, 2025 | prnewswire.comNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatesApril 7, 2025 | prnewswire.comNeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology MeetingApril 4, 2025 | prnewswire.comMarket Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS DrugMarch 20, 2025 | businesswire.comNeuroSense Advances PrimeC Commercialization in CanadaMarch 19, 2025 | tipranks.comPESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment LandscapeMarch 17, 2025 | businesswire.comLife Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense TherapeuticsMarch 12, 2025 | techbullion.comNeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS TreatmentFebruary 19, 2025 | tipranks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)February 4, 2025 | markets.businessinsider.comNeuroSense regains Nasdaq complianceJanuary 8, 2025 | markets.businessinsider.comNeurosense plans to license rights to advance PrimeC in certain regionsJanuary 7, 2025 | alsnewstoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationEVOK, JATT, MTEX, and NRSN Company DescriptionsEvoke Pharma NASDAQ:EVOK$2.96 +0.01 (+0.17%) Closing price 03:57 PM EasternExtended Trading$2.98 +0.03 (+1.02%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.JATT Acquisition NYSE:JATT$1.26 +0.11 (+9.57%) As of 06/6/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Mannatech NASDAQ:MTEX$10.39 -0.28 (-2.60%) Closing price 03:58 PM EasternExtended Trading$10.38 -0.01 (-0.13%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.NeuroSense Therapeutics NASDAQ:NRSN$1.90 +0.11 (+6.15%) Closing price 04:00 PM EasternExtended Trading$1.90 0.00 (0.00%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
